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Rheumatic heart disease 
(RHD) is a consequence 
of an earlier group A 
streptococcal infection and 
associated acute rheumatic 
fever (ARF). In Australia, 
RHD is particularly 
seen in Aboriginal and 
Torres Strait Islander 
peoples.1 However, with 
immigration from areas 
with a higher risk of RHD 
(Africa, South America 
and Asia2), it can also 
be seen in young, non-
Indigenous Australians. 
Generally, the onset of 
RHD occurs in childhood 
and adolescence; it affects 
more women than men. It 
can often be first detected 
in women of childbearing 
age and can potentially 
complicate pregnancy and 
labour. While the presence 
of RHD rarely means 
women cannot become 
pregnant, there are a 
number of factors that are 
important in ensuring a 
good outcome for both 
mother and child (see  
box below).
What is it? 
ARF is a non-infective response of a person’s immune system 
to an earlier throat infection with a common bacterium, group 
A streptococcus (GAS).3 It has also been suggested that skin 
infection with GAS may cause ARF though the evidence for this 
is less clear.4 The signs and symptoms of ARF include painful, 
stiff and swollen joints, fever, skin rash and heart and brain 
inflammation. In Australia, ARF is diagnosed on the basis of a 
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number of criteria, including: clinical signs and symptoms and the 
findings of ECG, echocardiography, throat swab and blood tests 
(see Table 1).
Table 1 Australian criteria for the diagnosis of ARF (see Diagnosis and 
management of acute rheumatic fever and rheumatic heart disease in 
Australia: An evidence-based review5 for more details)
High-risk groups All other groups
Initial episode 
of ARF
Two major OR one major and two minor 
manifestations PLUS evidence of preceding GAS 
infection
Recurrent 
episode of 
ARF if past 
ARF or RHD
Two major OR one major and two minor OR 
three minor manifestations PLUS evidence of 
preceding GAS infection
Major 
manifestations
1. Carditis (including 
RHD seen on 
echocardiogram 
without a murmur)
2. Polyarthritis 
or aseptic 
monoarthritis or 
polyarthralgia
3. Chorea
4. Erythema 
marginatum
5. Subcutaneous 
nodules
1. Carditis (excluding 
RHD seen on 
echocardiogram 
without a murmur)
2. Polyarthritis
3. Chorea
4. Erythema 
marginatum
5. Subcutaneous 
nodules
Minor 
manifestations
1. Fever
2. ESR	≥30mm/hr	
or	CRP≥30mg/L
3. Prolonged PR 
interval on 
ECG 
1. Fever
2. Polyarthralgia 
or aseptic 
monoarthritis
3. ESR	≥30mm/hr	or	
CRP≥30mg/L
4. Prolonged PR 
interval on ECG
RHD results from the cumulative effects of ARF-induced heart 
inflammation (carditis). It is a chronic heart condition associated with 
thickening and scarring of heart valves. This damage can affect the 
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Important factors in the early detection and management of RHD in women who are planning to become 
pregnant or who are pregnant
1. Detect early and exclude RHD 
a. In populations at high risk of RHD, all women who have a heart murmur require an early echocardiogram. 
b. If there is a history of ARF, the result of a recent echocardiogram should be reviewed.
2. Assess and treat before pregnancy 
a. Refer anyone with RHD for specialist physician/cardiologist review. 
b. Discuss fertility planning and contraception with women with RHD. 
c. Ensure fertility planning informs discussions regarding management in all women in whom surgery is planned.
3. Ensure a coordinated and multidisciplinary care team is in place early – pregnant women with RHD require a team approach linking 
primary healthcare, obstetric services, anaesthetics and specialist physicians/cardiologists.
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Specific recommendations for management of RHD and 
prosthetic heart valves in pregnancy
•	 Mitral regurgitation: generally tolerated well during pregnancy. 
Heart failure may require diuretics and vasodilators 
(hydralazine, nitrates, dihydropyridine calcium channel 
blockers). Vaginal delivery is usually possible when heart failure 
is controlled.
•	 Mitral stenosis: if moderate or severe often causes heart failure. 
If symptoms are not severe, medical therapy with diuretics, 
digoxin and/or beta-blockers to slow heart rate is indicated. 
If symptoms remain there is significant risk to both mother 
and fetus and relief of mitral stenosis is usually required. 
Percutaneous balloon valvuloplasy is preferred given the high 
risk of fetal loss with surgery. Vaginal delivery is the usual 
approach although caesarian section should be considered in 
cases of severe disease with severe pulmonary hypertension.
•	 Aortic stenosis: if mild or moderate can usually be safely 
followed during pregnancy. Severe disease involves significant 
risk of adverse outcomes and percutaneous balloon aortic 
valvuloplasty may be required.
•	 Prosthetic heart valves: choice of valve prosthesis in the 
childbearing age group is complicated by the fact that 
while tissue valves have the advantage of not requiring 
anticoagulation most will require later replacement. Most 
patients with prosthetic valves and few symptoms tolerate 
pregnancy well.
•	 Mechanical prosthetic valves and anticoagulation: mechanical 
valves are a high-risk group as all anticoagulation options 
pose maternal and/or fetal risks. Patients taking warfarin 
need early counselling and specialist advice before becoming 
pregnant. Women on warfarin who can become pregnant 
require reliable contraception.
See Diagnosis and management of acute rheumatic fever and 
rheumatic heart disease in Australia: An evidence-based review5 for 
more details.
function of valves (particularly the mitral and aortic valves) leading to 
leaking (regurgitation) or blockage (stenosis). More severe RHD can 
result in tiredness, shortness of breath, heart failure, infection of the 
heart valves (endocarditis)6 and stroke.2 During pregnancy, additional 
blood volume and workload on the heart can worsen many of these 
problems. In more severe RHD, surgery may be required to replace 
damaged valves with bioprosthetic (tissue valves derived from animals 
or humans) or mechanical valves, with the latter requiring lifelong 
anticoagulation (warfarin) to prevent clotting. In selected patients it 
may be possible to repair rather than replace valves at surgery or 
even open a stenosed mitral valve using less invasive percutaneous 
balloon mitral valvuloplasty.
Echocardiography is an essential tool in the diagnosis, assessment 
of severity and management of RHD. Like obstetric ultrasound, it 
is non-invasive and, with the development of smaller and portable 
echocardiography machines, it is now possible to provide local 
echocardiography services even to people living in very remote 
communities. This requires investment in suitable equipment 
and resourcing to ensure that there are mobile outreach 
echocardiography technicians or that staff providing visiting 
specialist outreach services have the requisite skill to perform 
echocardiography.
Epidemiology
The international incidence of ARF is almost 500 000 per year 
and 60 per cent of these cases will develop RHD each year. The 
prevalence of RHD is believed to be at least 15.6 million cases, 
with 282 000 new cases and 233 000 deaths each year.2
While there has been a decrease in the incidence and prevalence 
of ARF and RHD in industrialised countries during the past 50–100 
years, these diseases remain major public-health concerns in 
developing countries. However, there are some population groups 
in developed countries that remain at risk. This is the case within 
Figure 1. Echocardiography is both portable and accessible.
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Australia, where the acquisition of ARF and RHD is almost exclusively 
restricted to Aboriginal and Torres Strait Islander populations, 
particularly those living in rural and remote central and northern 
Australia. In these populations, the burden of ARF and RHD is among 
the highest in the world. The annual incidence of ARF in Aboriginal 
people in the Northern Territory has been reported as 250–350 per 
100 000 per year in the 4–15 age group, and the prevalence of RHD 
between 1.3 and 1.7 per cent (all ages).1 Similar levels of disease 
have been reported in northern Queensland and the Kimberley in 
the far north of Western Australia. By contrast, ARF in now rare in 
other Australian populations groups and the relatively small number 
of RHD cases seen in these groups occur mostly among the elderly 
and people born in Asia, Africa and South America who have 
subsequently migrated to Australia.
Management and antibiotic prophylaxis
In Australia, a guideline for the diagnosis and management of 
ARF/RHD has been published by the National Heart Foundation of 
Australia and the Cardiac Society of Australia and New Zealand.5 
This guideline has been adapted for local use by jurisdictions to 
reflect local healthcare systems.7–9 While the long-term priority 
for addressing ARF and RHD remains identifying effective targets 
for primary prevention, the current priority remains the secondary 
prevention of GAS infection with prophylactic antibiotics in those 
with a history of ARF or known RHD. The most effective form 
of secondary antibiotic prophylaxis is intramuscular benzathine 
penicillin, usually on a monthly (but ideally on a three-weekly) 
basis. This aims to prevent further attacks of ARF that could lead 
to the development of RHD in those with normal heart valves or 
worsen valve damage in those with the earliest changes of RHD.
RHD and women
Women are at higher risk of developing RHD compared with men, 
despite similar rates of ARF. A prospective surveillance program 
of ARF and RHD in Fiji between 2005 and 2007 revealed that 
the relative risk of admission for RHD for females compared with 
males was 2.5 (95 per cent CI, 1.6–3.8).10 A recent audit of the 
management of ARF and RHD, in the Kimberley region of Western 
Australia and Far North Queensland revealed a similar disparity 
in disease (see Figure 2). Of the 301 people with RHD 216 (71.8 
per cent, 95 per cent CI 66.3–76.8) were women. Overall, the 
odds of having RHD in women was 2.2 (95 per cent CI 1.6–3.1) 
compared with men.
The reasons for this far greater risk of RHD in women remain 
poorly understood. While it may be explained by a greater 
exposure to GAS in women caring for children, this would fail 
to explain the lack of a similar gender disparity in ARF incidence 
in younger people. It may also be, at least in part, attributable 
to women having a greater opportunity for diagnosis of RHD 
by accessing healthcare more frequently than men or a gender-
related predisposition to autoimmune disease.11
RHD in pregnancy
Pregnancy places an increased demand on the heart even in 
otherwise well women. Changes associated with pregnancy 
include an increase in blood volume and heart rate, a reduction 
in the resistance of the arterial circulation and an associated 
increase in cardiac output. These normal changes tend to worsen 
pre-existing heart valve problems, including those associated with 
RHD. For this reason it is not uncommon that RHD can sometime 
be first diagnosed in pregnancy through finding a heart murmur 
or the onset of heart failure. Unexplained shortness of breath in 
pregnancy and during and after delivery in patients at risk of RHD 
should always raise the suspicion of RHD and heart failure.
The National Heart Foundation of Australia and Cardiac Society 
of Australia and New Zealand’s Diagnosis and management of 
acute rheumatic fever and rheumatic heart disease in Australia: 
an evidence-based review5 highlights five maternal risk factors 
associated with RHD during pregnancy. These are: 
1. Reduced left ventricular function.
2. Significant aortic or mitral stenosis.
Gender Disparity in Cases of Acute Rheumatic Fever and Rheumatic Heart 
Disease in the Kimberley (Western Australia) and Far North Queensland
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Figure 2. Over-representation of women with RHD in the Kimberley (Western Australia) and Far North Queensland.
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3. Moderate or severe pulmonary hypertension.
4. A history of heart failure.
5. Symptomatic valvular disease before pregnancy. 
Health providers caring for pregnant women with RHD should refer 
to these guidelines for detailed advice (see box on p48). In general, 
regurgitant valve lesions are much better tolerated in pregnancy 
compared with stenotic lesions. Mitral and aortic stenosis should 
therefore raise particular concern. The importance of identifying RHD 
in women before they become pregnant is reinforced by the high 
risk of fetal loss associated with valve surgery during pregnancy. The 
key to RHD management in pregnancy remains early and regular 
monitoring by a multidisciplinary team. Management of labour and 
delivery in women with RHD and mechanical valves is complicated 
and is outlined in the review by Sartain.12
Conclusion
The normal cardiovascular changes associated with pregnancy 
exacerbate problems associated with pre-existing RHD and 
pregnant women with RHD must be managed according to 
the severity of their valve lesion and symptoms. Women with 
mechanical prosthetic valves who require anticoagulation are 
particularly at risk. The key to RHD management in pregnancy 
is detection and management before women become pregnant 
and early and regular multidisciplinary care in pregnancy, 
including primary healthcare providers, obstetricians, anaesthetists 
and specialist physicians/cardiologists. If managed early and 
proactively most women with RHD can become pregnant with a 
positive outcome for mother and child.
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helping to drive research excellence in women’s health
Membership of the Foundation
Membership of the RANZCOG Research Foundation is open 
to all members of the Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists and to all others with an interest in 
the aims and objectives of the Foundation.
By joining the RANZCOG Research Foundation you are directly 
contributing to the internationally recognised research conducted in 
Australia and New Zealand. 
Membership of the RANZCOG Research Foundation is free to all 
RANZCOG Fellows residing in Australia or New Zealand. Fellows 
wishing to accept membership of the Foundation should advise the 
RANZCOG Research Foundation Coordinator in writing.
Did You Know?
Supporting Research
The RANZCOG Research Foundation supports research in the 
fields of obstetrics, gynaecology, women’s health and the reproductive 
sciences through the awarding of various scholarships, fellowships 
and grants. 
The RANZCOG Research Foundation works closely with the RANZCOG 
Board, Council and College Committees to further the needs for 
research and research training in the broad fields of obstetrics, 
gynaecology, women’s health and the reproductive sciences.
Our Scholars
The Foundation proudly supports promising young Fellows, 
clinical researchers and scientists undertaking high quality, innovative 
research and research training at an early stage in their career.
Scholars supported by the RANZCOG Research Foundation have a 
strong record of subsequent achievement in research and in academic 
careers in Australia and overseas.
Grants and Scholarships 
Each year, approximately $120,000 is disbursed helping to 
support early career researchers in their work.
The Foundation continues to expand its program of grants, 
scholarships and other awards.  Recent initiatives include Collaborative 
Bachelor of Medical Science Research Scholarships, Project Grants 
to assist RANZCOG trainees in undertaking their research project 
and the Mary Elizabeth Courier Research Scholarship, introduced 
following a bequest to the Foundation by her late husband, Australian 
lithographic artist, Jack Courier. 
Further Information
Further information about the work of the Foundation is available 
on the website at: www.ranzcog.edu.au/research
Any questions should be directed to the RANZCOG Research 
Foundation Coordinator:
Ms Georgina Anderson: 
t: +61 3 9417 1699 
e: ganderson@ranzcog.edu.au
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